Related Experiment Video
Updated: Jan 4, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis
Melek Karakurt Eryılmaz1, Mustafa Karaağaç2
1Department of Medical Oncology, Hitit University Education and Research Hospital, Çorum, Turkey.
Abstract:
Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Kidney Transplant II: Surgical Procedure
Hemodialysis III: Nursing Management
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

